Genevieve Hale

Plozasiran: a small interfering RNA therapy for hypertriglyceridemia and familial chylomicronemia syndrome

Compared with earlier ApoC-III–targeted antisense oligonucleotides, plozasiran offers the advantages of less frequent dosing, sustained pharmacodynamic effects, and potentially a more favorable tolerability profile based on indirect evidence, positioning it as a promising therapeutic option for patients with FCS and ot...